A novel analgesic in a surgical model of osteoarthritis
Osteoarthritis is the most common form of joint disease affecting over 80% of the human
population above 75 years old and burdening health organizations worldwide. Osteoarthritis is
characterized by progressive joint degeneration resulting in chronic pain and loss of joint
function. Currently there is no cure for osteoarthritis; available treatments are only symptomatic
targeting pain and are associated with significant side effects, emphasizing the need for new
treatments.
Isovaline is a novel analgesic which showed remarkable effects in several pain models
without producing central nervous system side effects. The current study will examine the
analgesic profile of isovaIine in mice; we will assess the efficacy of isovaIine in alleviating the
signs of osteoarthritis and restoring the ability of the mice which underwent surgical
destabilization of the knee joint to exercise voluntarily. The effect of isovaline will be compared
to dicIofenac, and morphine the currently drugs of choice for osteoarthritic pain.
View Full Project DescriptionBernard Macleod
TherExcell Pharma Inc
Life Sciences
Manufacturing
The University of British Columbia
Accelerate